Fezakinumab

Fezakinumab
Monoclonal antibody
Type	Whole antibody
Target	IL-22
Clinical data
ATC code	none;
Identifiers
CAS Number	1007106-86-6 ;
ChemSpider	none;
UNII	0S77U25XZ3;
KEGG	D09615;
Chemical and physical data
Formula	C6408H9873N1706O2016S44
Molar mass	144479.04 g·mol−1
	(what is this?) (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]

Research and development

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data was not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.[4]

gollark: I have a thing which fills an array with secure random bytes and I want an integer from it, basically.

gollark: Nope.

gollark: I see.

gollark: Ideally, no unsafety.

gollark: Without just manually writing all the bitshifts and such.

References

"Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
"Archived copy" (PDF). Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.CS1 maint: archived copy as title (link)
"Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Lmt.projectsinknowledge.com. p. 4. Retrieved 2017-06-07.
Richardson, Brian. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018.

javascript:void(0);

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.

[2] "Archived copy" (PDF). Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.CS1 maint: archived copy as title (link)

[3] "Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Lmt.projectsinknowledge.com. p. 4. Retrieved 2017-06-07.

[4] Richardson, Brian. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018.